Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Correlation between Progression-Free Survival and Overall Survival in Patients with Relapsed Hodgkin Lymphoma: An Analysis of Individual Patient Data from Randomized GHSG Trials

Paul J Bröckelmann, Horst Müller, Sarah Gillessen, Anne Sophie Jacob, Jesko Momotow, Carla Damaschin, Justin Ferdinandus, Xiaoqin Yang, Michael Fuchs, Carsten Kobe, Hans Theodor Eich, Andreas Engert, Peter Borchmann, Bastian von Tresckow

Blood (2023) 142 (Supplement 1): 3070.

https://doi.org/10.1182/blood-2023-188622

Published: 2023

Journal Articles

Clinical Characteristics, Treatment Patterns, and Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Refractory to Covalent Bruton's Tyrosine Kinase Inhibitor (BTKi) and Exposed to B-Cell Lymphoma 2 Inhibitor (BCL2i)

Kevin H. Lin, Lynn Huynh, Xiaoqin Yang, Enrico Zanardo, Lisa Matay, Megan Pinaire, Daria Liborski, Mikaela M. McDonough, Jillian Foreman, Mohammed Z.H. Farooqui, Enrico De Nigris, Shravanthi R. Gandra, Eric M. Sarpong, Mei Sheng Duh, Jennifer R. Brown, Matthew S Davids

Blood (2023) 142 (Supplement 1): 1910.

https://doi.org/10.1182/blood-2023-182188

Published: 2023

Journal Articles

Correlation between Real-World Progression-Free Survival (rwPFS) and Overall Survival (OS) in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Relapsed or Are Refractory, Intolerant, Resistant to Treatment with a Bruton's Tyrosine Kinase Inhibitor (BTKi)

Blood (2023) 142 (Supplement 1): 4652.

https://doi.org/10.1182/blood-2023-180793

Published: 2023

Journal Articles

Patient Characteristics, Treatment Patterns, and Outcomes Following Covalent Btki Discontinuation in a Contemporary Cohort of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Patients

Kevin H. Lin, Lynn Huynh, Xiaoqin Yang, Neema Lema, Lisa Matay, Sobana Balasubramanian, Daria Liborski, Mikaela M. McDonough, Jillian Foreman, Mohammed Z.H. Farooqui, Enrico De Nigris, Shravanthi R. Gandra, Eric Sarpong, Mei Sheng Duh, Jennifer R. Brown, Matthew S. Davids

Blood (2022) 140 (Supplement 1): 4150–4152.

https://doi.org/10.1182/blood-2022-160389

Published: 2022

Journal Articles

Treatment Patterns of Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the Era of Targeted Therapy: A Real-World United States Study

Xiaoqin Yang, Enrico Zanardo, Dominique Lejeune, Enrico De Nigris, Eric Sarpong, Mohammed Z.H. Farooqui, Sidney M. Donzella, François Laliberté

Blood (2022) 140 (Supplement 1): 10932–10933.

https://doi.org/10.1182/blood-2022-163702

Published: 2022

Journal Articles

Healthcare Resource Utilization and Costs of Relapsed or Refractory Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Treated with Ibrutinib

Xiaoqin Yang, Enrico Zanardo, Dominique Lejeune, Enrico De Nigris, Eric Sarpong, Mohammed Z.H. Farooqui, François Laliberté

Blood (2022) 140 (Supplement 1): 10911–10912.

https://doi.org/10.1182/blood-2022-167262

Published: 2022

Journal Articles

Real-World Treatment Patterns and Outcomes after Ibrutinib Discontinuation Among Elderly Medicare Beneficiaries with Chronic Lymphocytic Leukemia: An Observational Study

Scott F. Huntington, Enrico De Nigris, Justin Puckett, Sachin Kamal-Bahl, Mohammed Z.H. Farooqui, Katherine Elizabeth Ryland, Eric Sarpong, Xiaoqin Yang, Jalpa Doshi

Blood (2022) 140 (Supplement 1): 7939–7940.

https://doi.org/10.1182/blood-2022-155903

Published: 2022

Journal Articles

Early-Stage Unfavorable Hodgkin Lymphoma: Patient Characteristics in Real-World Oncology Data from the United States

Santosh Gautam, Shweta Yeola, Akash Nahar, Eric Sarpong, Jennifer Prescott, Xiaoqin Yang, Helmneh Sineshaw

Blood (2022) 140 (Supplement 1): 12026.

https://doi.org/10.1182/blood-2022-157820

Published: 2022

Journal Articles

Real-World Analysis of Adverse Event Rates after Initiation of Ibrutinib Among Medicare Beneficiaries with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia By Ibrutinib Discontinuation Status

Enrico De Nigris, Scott F. Huntington, Justin Puckett, Sachin Kamal-Bahl, Mohammed Z.H. Farooqui, Katherine Elizabeth Ryland, Eric Sarpong, Xiaoqin Yang, Jalpa Doshi

Blood (2022) 140 (Supplement 1): 5043–5044.

https://doi.org/10.1182/blood-2022-162744

Published: 2022

Journal Articles

Healthcare Resource Utilization and Cost in Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma Who Received Autologous Stem Cell Transplantation in the US

Xiaoqin Yang, PhD, Kaushal D Desai, PhD MS, Adrienne M Gilligan, PhD, Monika Raut, Akash Nahar

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-136328

Published: 2020

Journal Articles

Real-World Conditional Survival Analysis of Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma in the US

Kaushal D Desai, PhD MS, Xiaoqin Yang, PhD, Adrienne M Gilligan, PhD, Yeran Li, PhD, Monika Raut, Akash Nahar

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-136424

Published: 2020

Journal Articles

Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the United States

François Laliberté, Monika Raut, Xiaoqin Yang, Guillaume Germain, MSc, Shuvayu S Sen, Sean D. MacKnight, Kaushal D Desai, Mei Sheng Duh

Blood (2019) 134 (Supplement_1): 4720.

https://doi.org/10.1182/blood-2019-128876

Published: 2019

Journal Articles

Healthcare Resource Utilization and Costs in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A U.S. Real-World Observational Study

Xiaoqin Yang, François Laliberté, Guillaume Germain, MSc, Monika Raut, Mei Sheng Duh, Shuvayu S Sen, Dominique Lejeune, Kaushal D Desai, Philippe Armand

Blood (2019) 134 (Supplement_1): 2133.

https://doi.org/10.1182/blood-2019-128368

Published: 2019

NARROW

Correlation between Progression-Free Survival and Overall Survival in Patients with Relapsed Hodgkin Lymphoma: An Analysis of Individual Patient Data from Randomized GHSG Trials

Clinical Characteristics, Treatment Patterns, and Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Refractory to Covalent Bruton's Tyrosine Kinase Inhibitor (BTKi) and Exposed to B-Cell Lymphoma 2 Inhibitor (BCL2i)

Correlation between Real-World Progression-Free Survival (rwPFS) and Overall Survival (OS) in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Relapsed or Are Refractory, Intolerant, Resistant to Treatment with a Bruton's Tyrosine Kinase Inhibitor (BTKi)

Patient Characteristics, Treatment Patterns, and Outcomes Following Covalent Btki Discontinuation in a Contemporary Cohort of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Patients

Treatment Patterns of Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the Era of Targeted Therapy: A Real-World United States Study

Healthcare Resource Utilization and Costs of Relapsed or Refractory Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Treated with Ibrutinib

Real-World Treatment Patterns and Outcomes after Ibrutinib Discontinuation Among Elderly Medicare Beneficiaries with Chronic Lymphocytic Leukemia: An Observational Study

Early-Stage Unfavorable Hodgkin Lymphoma: Patient Characteristics in Real-World Oncology Data from the United States

Real-World Analysis of Adverse Event Rates after Initiation of Ibrutinib Among Medicare Beneficiaries with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia By Ibrutinib Discontinuation Status

Healthcare Resource Utilization and Cost in Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma Who Received Autologous Stem Cell Transplantation in the US

Real-World Conditional Survival Analysis of Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma in the US

Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the United States

Healthcare Resource Utilization and Costs in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A U.S. Real-World Observational Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only